Zero Candida celebrates TSX Venture listing and debuts treatment for recurrent yeast infections [Video]

Zero Candida Co-Founder and CEO Eli Ben-Haroosh joined Steve Darling from Proactive to mark a significant milestone as the company opened the market in celebration of its listing on the TSX Venture Exchange under the ticker symbol ZCT. The listing highlights the company’s mission to revolutionize women’s health with its groundbreaking technology.

Zero Candida’s patented innovation leverages controlled “Blue Light” technology to effectively destroy fungal infections at unprecedented speed and without side effects. Delivered via a tampon-like medical device, this novel treatment offers a comprehensive solution for eliminating vulvovaginal candidiasis (VVC) and preventing its recurrence. VVC, commonly known as yeast infection, affects approximately 75% of women during their reproductive years. For 8-10% of women, these infections are recurrent, with four or more episodes annually.

Globally, 138 million women face recurrent infections every year, a number expected to rise to 158 million by 2030. Key factors contributing to recurrent VVC include …